Page 221 - Abstract Book KONIKA 18

Gastroenterohepatology

P-GEH-022
The Relationship of Interleukin-8 Levels between Helicobacter pylori and
Non-Helicobacter pylori Gastritis in Children

Maria, Supriatmo, Oke Rina Ramayani
Department of Child Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, Indonesia

Abstract
Background Gastritis is a gastrointestinal health problem that often occurs and is divided into acute and
chronic gastritis. Where the main cause of chronic gastritis is Helicobacter pylori infection. The number
of Interleukin-8 (IL-8) expressed by gaster epithelial cells in response to H. pylori is sufficient to induce
neutrophil chemotaxis, which is associated with a variety of gastrointestinal diseases including gastritis,
peptic ulcer cells, gaster carcinoma and gastric mucosa sufficient to induce neutrophil chemotaxis, which is
associated with various gastrointestinal diseases including gastritis, peptic ulcer cells, gastric carcinoma and
gastric mucosa sufficient to induce neutrophil chemotaxis, which is associated with various gastrointestinal
diseases including gastritis, peptic ulcer cells, gastric carcinoma and gastric mucosa-associated lymphoid-
tissue lymphoma. Objective To analysis the relationship of IL-8 levels in pediatric gastritis with and without
H. pylori infection. Methods A cross sectional study was conducted in outpatient and inpatient department
in three centers from March until April 2020. The diagnosis of H. pylori gastritis was confirmed by CLO
test. Blood sample was taken from subjects to evaluate IL-8 level. Results 60 subjects with gastrointestinal
complaints were reviewed. Subjects were divided into 2 groups based on CLO test, 29 subjects with
H. pylori infection and 31 subjects without H. pylori infection. From the analysis, mean IL-8 value was 25,86
pg/μ L and 10,99 pg/μL in helicobacter and non-helicobacter group, respectively (P<0,001). Conclusion
There are differences levels of IL-8 value between H. pylori gastritis and non-H. pylori gastritis in children.
Keywords: gastritis; Helicobacter pylori; interleukin-8

P-GEH-023
Fulminant Hepatic Failure and Myocarditis in COVID-19 Patient:
A Case Report of A 19-month-old Indonesian Boy

Eva J. Soelaeman , Evania A. Setiawan , Ariani D. Widodo , Dimas D. Saputro , Rifan Fauzie , Amar W.
1
1
1
1
2
Adisasmito 1
National Women and Chlidren Health Center, Harapan Kita Mother & Child Hospital and Child Health Department,
1
2
Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital , Jakarta, Indonesia
Abstract
Background Several manifestations of novel coronavirus disease 2019 (COVID-19) caused by corona
virus 2 (SARS-CoV-2) infection mostly included fever and respiratory symptoms. However, some of the
rare manifestations began to be widely reported. Objective To describe a confirmed COVID-19 pediatric
case with fulminant hepatic failure. Case A 19-month-old boy, weighed 10 kg, was admitted in our hospital
with diagnosis fulminant hepatitis (alanine aminotransferase 1356 U/L, total bilirubin 25.41 mg/dL) and
coagulopathy (prothrombine time >120 s, activated partial thromboplastin time 115.9 s). The patient developed
hepatic encephalopathy with episodes of hypoglycemia without any symptom of respiratory illness. He was
confirmed of Covid-19 by RT-PCR test with severe manifestation. Myocarditis was suspected based on
the increment of NT pro BNP (1100 pg/mL). Several tests were done to rule out other causes of fulminant
hepatitis. The results revealed negative for acute infection of viral hepatitis A, hepatitis B, hepatitis C,
cytomegalovirus, and toxoplasma. Several hepato-protectors, ursodeoxycholic acid, lactulose, and supportive
treatments for COVID-19 were administered, as well as enteral nutrition semi-elemental formula. The patient
was transferred from COVID-19 isolation ward after negative result of PCR SARS-CoV-2 test along with
the improvement of encephalopathy and liver function tests. Conclusion This case report describes the rare
clinical manifestations of SARS-CoV-2 infection. The incidence of fulminant hepatic failure should be
considered in those infected with SARS-CoV-2.
Keywords: fulminant hepatic failure; hepatic encephalopathy; COVID-19; SARS-CoV-2; children;
coronavirus

KONIKA XVIII Abstract Book 173